Drug Profile
Regavirumab
Alternative Names: MCA C23; TI 23Latest Information Update: 19 Oct 2000
Price :
$50
*
At a glance
- Originator Teijin Pharma
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 19 Oct 2000 Discontinued-preregistration for Cytomegalovirus infections in Japan (IV)
- 11 Oct 1999 Orphan Drug Designation for regavirumab has been withdrawan in Japan
- 11 May 1999 Investigation in Cytomegalovirus infections in Japan (IV)